MedTrace Logo

Phase I Orally Administered 14C-AZD2171 in Patients With Solid Metastatic Tumors

NCT00503412 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2009-01-19

No results posted yet for this study

Summary

Open, non-randomised, radiolabelled, single centre study with a total of six patients with solid metastatic tumors to determine the rates and routes of elimination of 14C-AZD2171 and its metabolites.

Conditions

  • Advanced Solid Metastatic Tumor

Interventions

DRUG

AZD2171

oral 14C

Sponsors & Collaborators

Principal Investigators

  • Nick Botwood, BSc, MBBS, MRCP, MFPM · AstraZeneca

  • Stan Kaye, Prod · Royal Marsden NHS Foundation Trust

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-11-30
Completion
2006-05-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00503412 on ClinicalTrials.gov